MassChallenge alum, Alkeus Pharmaceuticals has been selected as a top 15 promising private biotech company by FierceBiotech! Alkeus is making life better for kids with a previously untreatable disease:
“Alkeus has a trial-ready compound and a plan to rapidly build a body of evidence of its safety an
d efficacy for Stargardt. The genetic disorder, for which there are no approved drugs, afflicts 1 in 10,000 children and is the top cause of blindness in children.” -Alkeus Pharmaceuticals via FierceBiotech
Cellanyx offers a predictive, sensitive, and cost effective solution to inform physicians at the radical prostatectomy decision point. Cellanyx’s technology will improve the diagnostic process, increasing patient quality of life – significantly reducing health care costs.
Current tests can diagnose prostate cancer, but its harder to tell if your cancer is slow-growing or aggressive. Cellanyx Diagnostics is a new startup using novel biomarkers combined with microfluidic culture of biopsied tumor cells to assess the aggressiveness of prostate cancer. -Cellanyx Diagnostics via FluidicMEMS
Named Top 10 in NASA and Space Frontier Foundation’s New Technology for Space
Every year over 20 million children are not immunized and millions more perish from vaccine preventable diseases due to a lack of adequate vaccine refrigeration. Refrigeration alone can account for over 50% of the total cost of a vaccine.
Nanoly is scaling up a safe, proprietary polymer that stabilizes and protects temperature sensitive vaccines from manufacturing to the point of care with minimal change to the distribution channels, vial size, or administration of vaccines.
As we move into Awards season the companies are ramping up for Judging. Keep checking back for Finalist accomplishments and press; more is sure to come as we approach the October 23 Awards Ceremony!